Sartorius Stedim Biotech Presents A New Small-Scale Crossflow Device
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has launched the single- use ultrafilter Sartocon® Slice 50. The new crossflow filter device is designed for use in biotechnological applications, especially for membrane screening and small-volume process development.
Sartocon® Slice 50 is offered as an encapsulated and ready-to-use crossflow module with a filter area of 50 cm2 and a wide variety of molecular weight cutoffs. The cGMP validated self-contained unit eliminates the need for a compression holder and is available in a choice of two polymers: The Hydrosart® membrane is a stable polymer suitable for a broad pH range and can be depyrogenated using NaOH at elevated temperatures. It is extremely hydrophilic, making it non-protein-binding and virtually non-fouling, and delivers an exceptional high flux. The polyethersulfone membrane (PESU), which is well established in the biotechnological and pharmaceutical industries, is a stable polymer that is ideal for a broad pH and temperature range.
A major benefit of the new crossflow filter device is its linear scalability, along with identical materials of construction. This eases transfer of process development results to the next scale up level.
Sartocon® Slice 50 can easily be interfaced with SSB’s recently launched SARTOFLOW Smart benchtop crossflow system, as well as with many other laboratory-scale filtration systems.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and in 2015 earned sales revenue of 884.3 million euros according to preliminary figures. For more information, visit www.sartorius.com.